



Growth Spurt

Major Bioscience Expansions in Ohio fuel continued growth

As Ohio's bioscience industry is expanding, so are major company facilities and the jobs required to fill them.

According to a study released last December by BioOhio, the overall economic impact of Ohio-based bioscience was \$146 billion in 2006, representing 17.6% of Ohio's total economic output. Bioscience also directly and indirectly sustained 1.2 million jobs in Ohio that year.

By including three integrated sectors—commercial bioscience entities, hospitals and healthcare providers, and medical colleges—BioOhio's definition of the bioscience industry may be considered broad. However, even the state's commercial bioscience sector alone accounted for a \$27.3 billion overall economic impact and 48,485 direct jobs in 2006. When indirect and induced jobs are factored, the commercial bioscience employment figure jumps to 128,206.

Already impressive, these statistics undoubtedly will increase with a relatively silent but impressively steady string of major bioscience company expansions in all corners of the Buckeye State.

Flying high

In October 2007, Cardinal Health broke ground on a \$50 million, 250,000 square foot expansion of its Dublin, Ohio, headquarters. Cardinal Health is an \$87 billion company providing products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients.

The new west campus facility will house Cardinal Health's Healthcare Supply Chain Services division, a \$74 billion business that was formed through the combination of the company's pharmaceutical and medical products supply chain divisions.

At the groundbreaking, Ohio Gov. Ted Strickland said, "Cardinal Health is an inspiring example of Ohio's entrepreneurial spirit. Growing from a regional food distributor in 1971 to a global health care leader and the nation's 19th largest company today, Cardinal Health is showing the way to Ohio's economic renaissance."

The largest company in Ohio by revenue, Cardinal Health employs nearly 3,500 people across the state. With the completion of the new facility, slated for spring 2009, the company will add more than 700 additional jobs in Dublin.

Ohio two step

Fresh off a 2006 announcement to build their first-ever manufacturing plant, Amylin Pharmaceuticals announced last May the expansion of that plant already under construction in West Chester, a northern suburb of Cincinnati. The \$400 million expansion is expected to result in the creation of up to 500 jobs over the next three years.

The site is being designed to manufacture exenatide long-acting release (LAR), a diabetes drug candidate currently in clinical development, and full build-out is dependent on continued progress of exenatide LAR through its development process. Amylin already manufactures a twice-daily formulation of the drug under the brand name Byetta.

"Amylin's Ohio manufacturing facility is an important investment in our mission to deliver life-changing medicines to the patients we serve," said Amylin Pharmaceuticals President & CEO Daniel Bradbury. "We believe Ohio has a favorable business environment and is an ideal location for investing in our company's future growth."

More square feet for more employee feet

Upon receiving a 55%, 5-year job creation tax credit from the State of Ohio last December, Charles River Laboratories announced their decision to build a 58,000 square foot addition to its pre-clinical development facility in Spencerville.

A global provider of services and solutions that accelerate the drug discovery and development process, Charles River currently operates over 50 facilities in 15 countries worldwide.

The \$16 million investment in Ohio will add 80 new jobs to the current workforce of 200 over the next three years. According to company officials, construction is expected to be complete by mid-2009.

In addition to Ohio, Charles River had been considering Massachusetts, Nevada, and Quebec, Canada, for this expansion, three of six areas worldwide where Charles River has either completed new construction or is currently expanding existing plants.

21st Century growth

It seems that for much of the past decade, Bedford-based Ben Venue Laboratories has been in expansion mode. Ben Venue is part of the Boehringer Ingelheim group of companies and a leading producer of sterile injectable pharmaceutical products.

The company started construction last July on a \$71.5 million addition to an unfinished \$67 million building. The new 244,000 square feet plant will be devoted to the production of cytotoxic and genotoxic compounds used in cancer treatments. To prevent toxic drugs from contaminating nontoxic drugs, the new plant is isolated from other Ben Venue operations.

The expansion is scheduled to be completed by the end of this year and production will begin upon receiving regulatory approval. Ben Venue currently employs nearly 1,200 people. Company officials expect to hire an additional 150 to 200 people within two years of the new facility's completion.

Bricks & mortar for R&D

In 1985, specialty pharmaceutical company Eurand, based in Milan, Italy, opened its U.S. operations in Vandalia, near Dayton. On September 27, 2007, the company broke ground on a 13,000 square foot expansion to its 90,000 square foot research and manufacturing facility. The \$5.5 million investment also will include renovations in portions of the existing building. Completion is expected in 2009.

Eurand develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. In May 2007, Eurand successfully launched an initial public offering of 7 million ordinary shares priced at \$16 a share. The stock trades on NASDAQ under the symbol EURX.

“The expansion of our Vandalia facility will allow us to continue to provide innovative products to our current customer base while broadening our U.S. presence,” said Eurand CEO Gearóid Faherty. “This project underscores our commitment to research and development as a critical component of our future success.”

WIL's power

Like Charles River Labs, WIL Research Laboratories is benefiting from the recent surge in pharmaceutical R&D outsourcing. A non-clinical contract research organization based in Ashland, WIL Research opened the third and last phase of a major expansion project in November 2006. The new facility added 52,000 square feet of vivarium and new state-of-the-art bioanalytical, analytical and metabolism labs.

The \$34 million construction project, which began in 2005, totaled 100,000 square feet. The project is expected to create 80 new jobs and maintain 500 at the project site within the first three years.

Fast company

One of the fastest growing pharmaceutical companies in terms of relative growth and prescriptions, Prasco Pharmaceuticals moved into a new headquarters in Mason, Ohio, in July 2008. The company has successfully launched the largest number of authorized generics in the industry.

The new 28 acre campus includes 90,000 square feet of administrative offices, an 8,000 square feet multimedia auditorium, and an additional 70,000 square feet warehouse expansion. Always an eager and generous contributor to their community, the company also is building Prasco Park—a premier baseball diamond for select amateur baseball in the Midwest—on their new campus.

Passing the test

Advanced Testing Laboratory, a Blue Ash lab services and testing firm will soon add 200 jobs and more than double the size of its headquarters.

Advanced Testing Laboratory Inc. received a \$1.5 million state research and development loan to both acquire and renovate its facility. It will expand into 40,000

square feet, building labs and purchasing equipment to service the needs of companies in the pharmaceutical, medical device, health and beauty, and food and beverage industries.

Founded in 1987 by the current owner and company President Greg Neal, ATL was established in response to a strong need by the industrial community of Southwest Ohio and Northern Kentucky for high-quality technical and customizable laboratory testing services. Additional outsourcing from pharmaceutical and device companies has fueled ATL's recent growth spurt.

These examples underscore and contribute to the overall growth of Ohio's bioscience industry. With \$100 million in support from a bipartisan jobs stimulus package, the likelihood of even more bioscience company expansion is, well, expanding.